Sizing Up European Biosimilar Competition

A market’s structure and incentives are critical in ensuring that companies that develop medications like biosimilars have a competitive environment to thrive. Several countries in Europe implement tender systems, which are used to promote the lowest-cost biosimilar and may discourage competitors from contending after an unsuccessful bid. However, 2 officials of Medicines for Europe designed a scorecard of European markets to show which have robust biosimilar competition and which do not.

We sat down with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, to discuss their scorecard report for biosimilar access and what European countries they feel need the most work.